Rent expense, including common area maintenance fees for the three months ended May 31, 2019, and 2018 was $147,581 and $144,589, respectively, and $436,357 and $424,077 for the nine months ended May 31, 2019 and 2018, respectively. 
Total amortization expense for intellectual property agreements for the three months ended May 31, 2019 and 2018 was $232,292 and $231,042, respectively, and total amortization expense for the nine months ended May 31, 2019 and 2018 was $696,876 and $693,125 respectively. Accumulated amortization as of May 31, 2019 was $3,716,459 and $3,019,584 as of August 31, 2018. 
Revenue concentration shows that international sales accounted for 36% and 41% of net sales for the nine months ended May 31, 2019 and 2018, respectively. Three customers accounted for 9%, 8% (a dealer account in Japan representing various customers), and 7% of net sales during the nine months ended May 31, 2019. Three customers accounted for 9% (a dealer account in Japan representing various customers), 7% and 5% of net sales for the nine months ended May 31, 2018. 
During the three months and nine months period ended May 31, 2019 the Company recognized $116,000 and $749,000 of revenue that was included in contract liabilities as of August 31, 2018. 
On June 1, 2017, as part of the acquisition of DILIsym Services, Inc. the Company acquired certain developed technologies associated with the drug induced liver disease (DILI). These technologies were valued at $2,850,000 and are being amortized over 9 years under the straight-line method. Amortization expense for the three months and nine months ended May 31, 2019 and 2018 was $79,167 and $237,501, respectively, and is included in cost of revenues. Accumulated amortization as of May 31, 2019 and August 31, 2018 were $633,334 and $395,833, respectively. 
Amortization expense for each of the three-month and nine-month periods ended May 31, 2019 and 2018 was $89,375 and $268,125, respectively. According to policy, in addition to normal amortization, these assets are tested for impairment as needed. 
On February 28, 2012, we bought out a royalty agreement with Enslein Research of Rochester, New York. The cost of $75,000 is being amortized over 10 years under the straight-line method. Amortization expense for each of the three-month periods ended May 31, 2019 and 2018 was $1,875 and was $5,625 for each of the nine-month periods ended May 31, 2019, and 2018. Accumulated amortization as of May 31, 2019 and August 31, 2018 were $54,375 and $48,750, respectively. 
Amortization of capitalized software development costs is calculated on a product-by-product basis using the straight-line method over the estimated economic life of the products (not to exceed five years). Amortization of software development costs amounted to $322,552 and $331,862 for the three months ended May 31, 2019 and 2018, respectively, and $1,006,339 and $952,894 for the nine months ended May 31, 2019 and 2018, respectively. We expect future amortization expense to vary due to increases in capitalized computer software development costs. 
The Company designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students, and it provides consulting services to the pharmaceutical and chemical industries. Recently, the Company has begun to explore developing software applications for defense and for health care outside of the pharmaceutical industry. Net income increased by $483,000 million, or 20.1%, in 3QFY19 to $2.9 million from $2.4 million in 3QFY18. The increase in net income comes mainly from increased revenues.  
Consolidated gross margin increased $2.10 million or 12.3%, to $19.21 million in 9moFY19 from $17.10 million in 9moFY18. The Lancaster division’s gross margin increased $982,000 or 8.2%, resulting in a gross margin percentage of 84.0%. The Buffalo division’s gross margin increased $344,000 or 10.4%, resulting in a gross margin percentage of 53.2%, and DILIsym of North Carolina showed an increase in gross margin of $779,000 or 42.4%, resulting in a 71.7% gross margin percentage. 
Cost of Revenues as a percentage of revenues decreased slightly by 0.3% in 3QFY19 to 23.4% as compared to 23.7% in 3QFY18. 
Cost of Revenues as a percentage of revenue increased by 0.4% in 9moFY19 to 26.0% as compared to 25.6% in 9moFY18. 
Income from operations increased $464,000 or 13.6% in 3QFY19 compared to 3QFY18. 
Income from operations increased $300,000 or 3.6% in 9moFY19 compared to 9moFY18. 
Comparison of Three Months Ended May 31, 2019 and 2018. 
Overall gross margin as a percentage of revenue decreased by 0.4% to 74.0% in 9moFY19 from 74.4% in 9moFY18.   Item 1. Legal Proceedings  